CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2540493
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1
Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1
创建时间：
2021-05-15
